Craft
Kadmon

Kadmon

Revenue

$8.3 M

FY, 2020

Market Capitalization

$1.6 B

2021-11-09

Kadmon Summary

Company summary

Overview
Kadmon is a biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology, and genetic diseases. 
Type
Public
Status
Active
Founded
2010
HQ
New York, NY, US | view all locations
Website
http://kadmon.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Tasos G. Konidaris, Chairman of the Board

    • Harlan W. Waksal

      Harlan W. Waksal, President, Chief Executive Officer and Director

      • Steven Meehan

        Steven Meehan, Executive Vice President, Chief Financial Officer

        • Eugene Bauer, Director

          LocationsView all

          4 locations detected

          • New York, NY HQ

            United States

            450 E 29th St

          • Cambridge, MA

            United States

            55 Cambridge Pkwy

          • South Brunswick Township, NJ

            United States

            1 Deerpark Dr ste h - 4, Monmouth Junction

          • Warrendale, PA

            United States

            119 Commonwealth Dr

          Kadmon Financials

          Summary financials

          Revenue (Q3, 2021)
          $14.7M
          Gross profit (Q3, 2021)
          $14.1M
          Net income (Q3, 2021)
          ($33.0M)
          Cash (Q3, 2021)
          $68.8M
          EBIT (Q3, 2021)
          ($26.4M)
          Enterprise value
          $181.1M

          Footer menu